Lijuan Fan1, Guoning Fu1, Yuanyuan Ding1, Peng Lv1, Hongyun Li2. 1. Department of Gastroenterology, Jining First People's Hospital, No. 6 health Road, Jining, Shandong Province, 272000, China. 2. Department of Gastroenterology, Jining First People's Hospital, No. 6 health Road, Jining, Shandong Province, 272000, China. xhlhy1998@163.com.
Abstract
OBJECTIVE: Bactericidal/permeability increasing protein (BPI) gene polymorphisms have been extensively investigated in terms of their associations with inflammatory bowel disease (IBD), with contradictory results. The aim of this meta-analysis was to evaluate associations between BPI gene polymorphisms and the risk of IBD, Crohn's disease (CD), and ulcerative colitis (UC). METHODS: Eligible studies from PubMed, Embase, and Cochrane library databases were identified. RESULTS: Ten studies (five CD and five UC) published in five papers were included in this meta-analysis. G645A polymorphism was associated with a decreased risk of UC in allele model, dominant model, and homozygous model. CONCLUSIONS: Our data suggested that BPI G645A polymorphism was associated with a decreased risk of UC; the BPI G645A polymorphism was not associated with the risk of CD.
OBJECTIVE:Bactericidal/permeability increasing protein (BPI) gene polymorphisms have been extensively investigated in terms of their associations with inflammatory bowel disease (IBD), with contradictory results. The aim of this meta-analysis was to evaluate associations between BPI gene polymorphisms and the risk of IBD, Crohn's disease (CD), and ulcerative colitis (UC). METHODS: Eligible studies from PubMed, Embase, and Cochrane library databases were identified. RESULTS: Ten studies (five CD and five UC) published in five papers were included in this meta-analysis. G645A polymorphism was associated with a decreased risk of UC in allele model, dominant model, and homozygous model. CONCLUSIONS: Our data suggested that BPIG645A polymorphism was associated with a decreased risk of UC; the BPIG645A polymorphism was not associated with the risk of CD.
Authors: Ivonne Petermann; Claudia Huebner; Brian L Browning; Richard B Gearry; Murray L Barclay; Martin Kennedy; Rebecca Roberts; Andrew N Shelling; Martin Philpott; Dug Yeo Han; Lynnette R Ferguson Journal: Hum Immunol Date: 2009-03-09 Impact factor: 2.850
Authors: R S Walmsley; M H Zhao; M I Hamilton; A Brownlee; P Chapman; R E Pounder; A J Wakefield; C M Lockwood Journal: Gut Date: 1997-01 Impact factor: 23.059